MLD's Plasmalogen Drug PPI-1040 for RCDP receives FDA Orphan Drug Designation (ODD)

MLD is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted PPI-1040, a proprietary synthetic plasmalogen replacement, Orphan Drug Designation (ODD) for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP).

For more information on RCDP and the ODD program see our blog post linked below.